Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sitravatinib

Phase 3Small molecule

MMirati Therapeutics Inc.

Sitravatinib is an experimental drug being studied to treat certain types of cancer, particularly those with specific genetic mutations that make cancer cells grow.[1] Sitravatinib is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]

Sitravatinib is one of 117 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 3.

3

Indications

31

Total Trials

4

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Biliary Tract CancerActive, not recruiting

Non-Small Cell Lung CancerTerminated

Advanced MalignanciesEnrolling by invitation

Biliary Tract CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Terminated

Advanced MalignanciesPhase 3

Enrolling by invitation

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Ensacove

XXcovery Holdings, Inc.

Nanocrystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Pemetrexed+cisplatin

Sitravatinib

MMirati Therapeutics Inc.

Remeron

OOrganon and Co

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

PD-1 Inhibitors

BBioNTech US Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Metastatic Breast Cancer

NCT04734262

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Terminated· BeiGene logo

BeiGene·Phase 3·NCT04921358·377 enrolled

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT02664935·423 enrolled

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Terminated·MMirati Therapeutics Inc.·Phase 2·NCT02954991·161 enrolled

Hepatocellular Carcinoma2 trials

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Withdrawn· BeiGene logo

BeiGene·Phase 3·NCT05564338

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Completed· BeiGene logo

BeiGene·Phase 1/2·NCT03941873·111 enrolled

Interaction2 trials

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04887194·40 enrolled

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

Completed·MMirati Therapeutics Inc.·Phase 1·NCT05255276·36 enrolled

Renal Cell Carcinoma2 trials

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Completed·MMirati Therapeutics Inc.·Phase 2·NCT03680521·25 enrolled

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04518046·22 enrolled

Locally Advanced1 trial

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Terminated·FFudan University·Phase 2·NCT05176925·5 enrolled

21 more indications

Hepatic Impairment1 trial

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04772612·30 enrolled

Renal Cell Cancer1 trial

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04904302·15 enrolled

Maintenance Therapy1 trial

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05228496·21 enrolled

Kidney Cancer1 trial

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03015740·42 enrolled

Non-squamous NSCLC1 trial

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Terminated·SSarah Goldberg·Phase 2·NCT04925986·9 enrolled

Age1 trial

A Study to Explore the Effect of Acid-reducing Agents

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04935112·15 enrolled

Urothelial Carcinoma1 trial

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Terminated·MMirati Therapeutics Inc.·Phase 2·NCT03606174·260 enrolled

Adult1 trial

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Completed· BeiGene logo

BeiGene·Phase 1·NCT04472650·26 enrolled

Breast Cancer1 trial

Sitravatinib in Metastatic Breast Cancer

Terminated·XXiang Zhang·Phase 2·NCT04123704·3 enrolled

Advanced Malignancies1 trial

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation·BBeOne Medicines·Phase 3·NCT04164199·430 enrolled

Single Dose1 trial

A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04800614·36 enrolled

Cervical Cancer1 trial

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

Withdrawn·AAustralia New Zealand Gynaecological Oncology Group·Phase 2·NCT05614453

Oral Cavity Cancer1 trial

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

Completed·UUniversity Health Network, Toronto·Phase 1·NCT03575598·10 enrolled

Metastatic Melanoma1 trial

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05104801·37 enrolled

Advanced Solid Tumors1 trial

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT03666143·216 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Terminated· BeiGene logo

BeiGene·Phase 2·NCT05461794·96 enrolled

Endometrial Cancer1 trial

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Withdrawn·HHaider Mahdi·Phase 2·NCT05419817

Biliary Tract Cancer1 trial

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04727996·43 enrolled

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE

Terminated·MMirati Therapeutics Inc.·Phase 3·NCT03906071·577 enrolled

Metastatic Breast Cancer1 trial

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Active, not recruiting·FFudan University·Phase 2·NCT04734262·98 enrolled

Solid Malignancies1 trial

A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies

Completed·MMirati Therapeutics Inc.·Preclinical·NCT04887870·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for Sitravatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sitravatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sitravatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirati Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMirati Therapeutics Inc.

Related News